7th Eurasian Hematology Oncology Summit
How I Treat Frontline CML in 2020: Does Imatinib Improve Long-Term Survival vs. Nilotinib? When Should We Adjust TKI Dose?
By
7th Eurasian Hematology Oncology Summit
FEATURING
Hagop Kantarjian
By
7th Eurasian Hematology Oncology Summit
FEATURING
Hagop Kantarjian
Login to view comments.
Click here to Login
